Mar. 20 at 3:21 PM
$NNVC: The Broad-Spectrum Antiviral Play No One’s Watching
NanoViricides is developing broad spectrum antivirals that bind to and neutralize viruses directly.
Their lead candidate (NV-387) targets COVID, flu, RSV, and Mpox, aiming for a platform, not a single drug.
Recent milestones
🔸Completed Phase 1 safety trials
🔸Advanced manufacturing for Phase 2-ready drug
🔸Preparing for Phase 2 (Mpox focus)
Catalysts
🔸Phase 2 launch + data
🔸Expansion into additional viral targets
🔸Regulatory updates / partnerships
The antiviral market is already ~
$60–70B, with long-term growth toward ~
$90B+
NNVC is a microcap trying to capture that with a multi-virus approach
Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC
Peers:
$PFE $MRNA $BNTX $GILD
